Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Pseudomonas Stories

2009-04-21 09:00:00

Presently No Approved Treatments MONMOUTH JUNCTION, N.J., April 21 /PRNewswire/ -- Transave, Inc., today reported completion of patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace(TM) (liposomal amikacin for inhalation) in non-cystic fibrosis (CF) bronchiectasis patients. The results, which are expected to be available by mid-year, will shed new light on how this patient population responds to treatment. Presently, there are no approved treatments for the...

2009-04-13 15:35:02

U.S. medical researchers say they have discovered a lack of the mineral phosphate can turn a common bacterium -- Pseudomonas aeruginosa -- into a killer. University of Chicago scientists said their finding could lead to new drugs that would disarm the increasingly antibiotic-resistant pathogen rather than kill it. Pseudomonas aeruginosa, one of the most serious hospital-acquired pathogens, is a common cause of lung infections. It is found in the intestinal tract of 20 percent of all Americans...

2009-04-09 07:44:23

'Red Death' provides clues about how P. aeruginosa attacks hostLack of an adequate amount of the mineral phosphate can turn a common bacterium into a killer, according to research to be published in the April 14, 2009, issue of the Proceedings of the National Academies of Science. The findings could lead to new drugs that would disarm the increasingly antibiotic-resistant pathogen rather than attempting to kill it. Pseudomonas aeruginosa is one of the most serious hospital-acquired...

2009-03-26 03:30:00

PARIS, March 26 /PRNewswire-FirstCall/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today the appointment of Dr. Karen Bush to the Company's Scientific Advisory Board (SAB). Novexel's SAB is chaired by Dr. David Shlaes who sits on the Company's board. Dr. Bush, who is currently Adjunct Professor at the Department of Biology at Indiana...

2009-03-24 08:44:04

Researchers at National Jewish Health have discovered a promising strategy for destroying the molecular scaffolding that can make Pseudomonas bacterial infections extremely difficult to treat in cystic fibrosis patients, wearers of contact lenses, and burn victims. Jerry Nick, MD, Associate Professor of Medicine at National Jewish Health, and his colleagues report in the April 2009 issue of The Journal of Medical Microbiology that a long string of aspartic acid molecules disrupts the...

2009-03-23 23:01:00

SAN DIEGO, March 24 /PRNewswire/ -- Calixa Therapeutics Inc. today announced positive results from a Phase 1 trial of intravenous CXA-101, a novel cephalosporin antibiotic with excellent in vitro anti-pseudomonal activity. The results from this first Phase 1 study demonstrated that CXA-101 was well tolerated, with a clinical and laboratory safety profile similar to that of marketed cephalosporin antibiotics. No dose-limiting toxicity was observed, even at the highest dose regimen evaluated....

2009-03-18 09:14:15

The unexpected behaviour of a family of "superbugs" called the Burkholderia cepacia complex (Bcc) could have implications for the treatment of cystic fibrosis (CF) patients. CF patients produce large quantities of sticky mucus in their lungs that is difficult to expel and is easily infected by bacteria. A recent treatment for CF, inhalation of a sugar called mannitol, works by attracting moisture into the lungs. This thins the mucus making it easier to disperse. However, recent research by...

2009-03-16 13:18:30

U.S. medical scientists say they have discovered a new method to prevent bacterial infections by using the body's own enzymes. Dr Quinn Parks and colleagues at Denver's National Jewish Health Hospital said they used enzymes against products of the body's own defense cells to prevent Pseudomonas aeruginosa bacteria from building a protective biofilm that enables the bacteria to avoid both the body's immune mechanisms and antibiotics. When the body's defense cells, called neutrophils, attack P....

2009-03-03 07:00:00

Merck's Drug Will Remain Decision Resources Gold Standard Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., March 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a broad-spectrum intravenous antibiotic that has activity against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), shows higher efficacy than the current benchmark (Wyeth's...

2009-01-30 07:00:00

First Diagnostic Test for Identifying E. coli and P. aeruginosa Directly from Positive Blood Cultures PNA FISH to Provide Critical Results 24-48 Hours Sooner Than Conventional Methods Helping Clinicians to Improve Care and Outcomes for 100,000 Patients with Bloodstream Infections WOBURN, Mass. and VEDBAEK, Denmark, Jan. 30 /PRNewswire/ -- AdvanDx today announced it received FDA 510(k) clearance for E. coli/P. aeruginosa PNA FISH(R) to identify Escherichia coli and/or Pseudomonas aeruginosa...


Latest Pseudomonas Reference Libraries

0_85d9abd5d0844260722ff2e72fcc9f5a
2011-04-25 21:18:54

Pseudomonas aeruginosa is a common bacterium that can cause disease in animals and humans. It can be found in soil, water, skin flora, and most man-made environments throughout the world. It thrives in normal or hypoxic atmospheres; due to this it has colonized many natural and artificial environments. It can infect animals with damaged tissue or people with reduced immunity. Symptoms are generalized inflammation and sepsis. It can be fatal if colonization occurs in critical body organs,...

More Articles (1 articles) »